Roche sold CHF1billion (approx 1.14 billion Australian dollars) in the first half of this year compared to GSK sold $304.4 million of Relenza and presold 190 million doses of yet-to-be-available Pandemic Flu Vaccine.
Should read: Roche sold CHF1billion (approx 1.14 billion Australian dollars) in the first half of this year compared to GSK sold $638.7 million of Relenza and presold 190 million doses of yet-to-be-available Pandemic Flu Vaccine.
- $1.14 billion of the inferior Tamilu is sold for the first half year compared to $204.4 million of the superior Relenza for the full year and - Roche is gearing up production capacity to 400 million packs compared to GSK’s 190 million courses.
Should read: - $1.14 billion of the inferior Tamilu is sold for the first half year compared to $638.7million of the superior Relenza for the full year and - Roche is gearing up production capacity to 400 million packs compared to GSK’s 190 million courses.
BTA Price at posting:
$1.88 Sentiment: None Disclosure: Not Held